Management of Stage I Nodular Lymphocyte-Predominant Hodgkin Lymphoma of Cervical Lymph Nodes
For stage I nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) confined to cervical lymph nodes, involved-field radiotherapy (IF-RT) at 30 Gy alone is the standard treatment, offering excellent tumor control with minimal toxicity. 1
Treatment Algorithm
Stage IA Without Risk Factors
- Primary recommendation: IF-RT 30 Gy alone 1, 2, 3
- This approach provides 8-year progression-free survival of 91.9% and overall survival of 99.0% 4
- Avoids chemotherapy-related toxicity while maintaining excellent disease control
- NLPHL has a distinct natural history from classical Hodgkin lymphoma, justifying this less intensive approach 5
Stage IA With Risk Factors or Stage IIA
Multiple acceptable options exist, listed by intensity:
Combined modality therapy (preferred for unfavorable features):
- 2 cycles ABVD followed by 20-30 Gy ISRT 3
- Provides superior tumor control compared to RT alone
Chemotherapy ± rituximab ± IF-RT 5
- Consider rituximab addition given CD20+ phenotype of LP cells
- 4-6 cycles ABVD if chemotherapy-only approach chosen
Observation after complete surgical excision (highly selected cases) 6
- May be considered particularly in pediatric patients with completely resected stage IA disease
Key Clinical Considerations
Why NLPHL Differs from Classical HL
- Immunophenotype: CD20+/CD30-/CD15- (versus CD20-/CD30+/CD15+ in classical HL) 1
- Natural history: Indolent course with tendency to recur but excellent long-term survival 1
- Treatment response: Responds to both HL-directed therapy and B-cell NHL approaches due to CD20 expression
Risk Factors to Assess
When determining if stage IA is truly "favorable":
- B symptoms (fever, night sweats, weight loss >10%)
- ESR >50 with B symptoms or >30 without 1
- Multiple lymph node areas (≥3 sites)
- Large mediastinal mass (>1/3 horizontal chest diameter)
- Extranodal disease
- Variant immunoarchitectural patterns (though recent data questions prognostic significance) 7
Critical Pitfall: Relapse Evaluation
Always obtain repeat biopsy at suspected relapse 2 - NLPHL has substantial risk of transformation to aggressive B-cell NHL, which fundamentally changes management. The transformation rate is higher than historically reported 2.
Relapsed Disease Management
For cervical node recurrence after initial RT:
- Localized relapse: Rituximab monotherapy is highly effective given CD20 expression 1, 2
- More extensive relapse: Chemotherapy ± rituximab, chosen individually based on prior treatment and relapse timing 8
- Early recurrence/poor-risk features: Consider aggressive salvage with high-dose chemotherapy and autologous stem cell transplantation 8
Monitoring After Treatment
- First 6 months: Every 3 months (history, physical exam, labs including CBC, ESR, chemistry)
- Years 1-4: Every 6 months
- After year 4: Annually 2
- Thyroid function: Monitor TSH at 1,2, and ≥5 years post-neck RT 2
- CT imaging: Only once to confirm remission, then only for suspicious symptoms 2
- Cancer screening: Regular surveillance for secondary malignancies, particularly after RT exposure 2
Why Not More Aggressive Treatment?
The excellent prognosis of stage I NLPHL (overall survival >95-99% at 8 years) 4 means treatment de-escalation is appropriate to minimize long-term toxicity including:
- Secondary malignancies (6.6% incidence in long-term follow-up) 4
- Cardiac toxicity from anthracyclines
- Pulmonary toxicity from bleomycin
- Infertility from chemotherapy
The goal is cure with minimal treatment-related morbidity, not maximum initial intensity.